NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

Cytosorbents Corporation (CTSO) Stock Analysis

Cytosorbents Corporation (CTSO) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

CTSO

$0.35

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CTSO with… →

CTSO Key Statistics

As of Sep 4, 2026
Trading
Open
$0.35
Previous Close
$0.35
Day's Range
0.34–0.37
52-Week Range
0.30–1.04
Volume
438.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.34
Valuation
Market Cap
$22.00M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.59
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.29
Financials (FY)
Revenue (FY)
$37.06M+4.12%
Net Income (FY)
−$8.20M
Profit marginThe share of revenue left as profit after all costs and taxes.
−48.94%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
62.84M
1-Year Return
−64.14%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
240.86K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CTSO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−45.23%
2025−29.78%
2024−18.02%
2023−28.39%
2022−63.01%
2021−47.43%
2020+107.01%
2019−52.35%
2018+24.31%
2017+19.27%
2016 (partial year)+11.45%

As of September 4, 2026.

CTSO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$37.06M−$8.20M−22.1%
2024$35.60M−$20.72M−58.2%
2023$31.08M−$29.25M−94.1%
2022$29.36M−$32.81M−111.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$37.06M$26.49M−$14.24M−$8.20M−22.1%
2024$35.60M$24.89M−$16.45M−$20.72M−58.2%
2023$31.08M$21.95M−$31.95M−$29.25M−94.1%
2022$29.36M$15.40M−$31.52M−$32.81M−111.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CTSO Valuation vs Medical Devices Median

Median of 151 stocks
MetricCTSOMedical Devices medianvs median
P/S ratio0.592.980.2x the median
Profit margin−48.94%−1.69%47.3 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Cytosorbents Corporation (CTSO) at $22.00M. The company sits in the Healthcare sector, in the Medical Devices industry. The company reports 129 employees.

CTSO last closed at $0.35 on September 4, 2026. The close was unchanged from the previous session. The 52-week range on file runs from $0.30 to $1.04. The latest close sits 16.67% above that 52-week low.

Financial Health

In fiscal 2025, Cytosorbents Corporation reported revenue of $37.06M. That is +4.12% against the prior fiscal year, when revenue was $35.60M. The same year closed with a net loss of $8.20M. The reported profit margin is −48.94%. That is 47.3 percentage points below the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −0.29.

Across the 4 fiscal years on file, revenue moves from $29.36M in 2022 to $37.06M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 0.59. On price-to-sales that is 0.2 times the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

The trailing one-year price return is −64.14%. Measured over 10 years, that is −23.64% a year compounded. Beta against the wider market is reported at 1.34. Annualized volatility over the trailing 10 years is 74.61%.

Growth & Income

No dividend is on file for CTSO.

Across the complete calendar years on file, 2020 returned +107.01% and 2022 returned −63.01%. Of the 9 complete calendar years on file, 3 finished higher. 2026 is still running; the price is −45.23% year to date.

Peer Comparison

Cytosorbents Corporation (CTSO) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cytosorbents Corporation CTSO $22.00M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Cytosorbents Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Cytosorbents Corporation

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Visit website →